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Abstract
Background: Genetic analyses showed that the triggering receptor expressed in myeloid cells 2 (TREM2) p.R47H
variant increases the risk for Alzheimer’s disease (AD). The question of whether the p.R47H mutation affects
expression or function of the receptor remains unanswered. To address this question we quantified mRNA and
analyzed protein profiles of WT and p.R47H TREM2 in human brains.
Methods: Quantitative real-time PCR (qPCR) was performed using 2 sets of primers one that detects all TREM2
mRNA isoforms and one specific for the alternative spliced isoform (TREM2alt) that encodes for the extracellular
domain (soluble TREM2). Because in the brain TREM2 is expressed primarily in microglial cells, we also assessed the
levels of IBA1 to control for microglial variability across samples. For TREM2 protein quantitation and N-glycosylation
processing, RIPA brain extracts were analyzed by Western blot before and after EndoH and PNGaseF treatments.
Results: We identified statistically significant increased levels of TREM2 transcripts in the temporal cortex of AD
subjects when compared with controls; TREM2alt was likewise higher in AD cases, but was not significant after
adjustment for covariates. Quantitative analysis of TREM2 protein confirmed qPCR results that showed higher levels
in AD than in control brains. Among AD subjects, we observed a trend towards higher mRNA and protein TREM2
levels in carriers of the p.R47H risk allele. Analysis of individual TREM2 species found no difference in the relative
amounts of mature and immature species, and carboxyl terminal fragments between non carriers and p.R47H
samples. Furthermore, TREM2 species from either non carriers or p.R47H brains were equally susceptible to EndoH
and PNGaseF treatments.
Conclusions: Our results suggest that TREM2 expression is increased in AD. Furthermore, we provide evidence
indicating that p.R47H mutation does not affect the levels of TREM2 either directly by altering expression or
indirectly by affecting processing of the protein. Our data support previous findings that suggest that p.R47H
variant affects TREM2 function by altering binding properties of the receptor rather than expression.
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Introduction
Alzheimer’s disease (AD) is the leading cause of dementia
in the elderly. AD pathology is characterized by extracellu-
lar plaques composed primarily of amyloid beta protein
(Aβ) and intracellular neurofibrillary tangles composed
primarily of hyperphosphorylated tau. According to the
amyloid cascade hypothesis, neurofibrillary tangles and
the neuroinflammation invariably observed in AD are
downstream events caused by Aβ accumulation [1]. There
is mounting evidence, however, that the innate immune
system plays an important role in AD. Support for
involvement of innate immunity came from genetic and
integrated system studies as follows. i) Network-based in-
tegrative analysis identified an immune/microglia mod-
ule as one of the molecular systems most strongly
associated with the pathophysiology of late onset AD
[2]. ii) Genome-wide association studies identified
genes of the immune system in general (CLU and
MS4A) and of microglia function in particular (CD33
and CR1), in or close to the risk loci for late onset AD
[3, 4]. iii) Heterozygous variants in triggering receptor
expressed in myeloid cells 2 (TREM2), which encodes
for a microglia receptor, associate with increased risk
for AD. [5, 6]. Among these rare variants, p.R47H is
the most commonly found associated with AD.
TREM2 belongs to the TREM family of receptors
whose members are cell surface glycoproteins posses-
sing an immunoglobulin-like extracellular domain, a
transmembrane region, and a short cytoplasmic tail. In
the brain, TREM2 is involved in regulation of the
microglia inflammatory response and phagocytosis of
cell debris. The receptor relies entirely on the adaptor
protein DAP12 (aka TYROBP) for intracellular signal-
ing, and this partnership is absolutely required for effi-
cient phagocytosis [7].
Loss of function for either TREM2 or DAP12 has
clinical implications, resulting in polycystic lipomem-
branous osteodysplasia with sclerosing leukoencepha-
lopathy (PLOSL), a rare and fatal disease also known
as Nasu Hakola disease, characterized by bones cysts
and late-onset dementia [8, 9]. Although, the mechan-
ism behind the pathology in PLOSL is not known, one
hypothesis is that lack of either TREM2 or DAP12
activity impairs the clearance of apoptotic neurons by
microglia, leading to the accumulation of necrotic
debris [10].
It was recently demonstrated that TREM2 undergoes a
proteolytic cleavage that releases its extracellular domain,
leaving a carboxy terminal fragment (CFT) attached to the
membrane [11]. In addition to the membrane-bound
form, a soluble form of TREM2 (sTREM2) is detectable in
plasma and CSF [12]. It is assumed that sTREM2 origi-
nates by the release of the receptor extracellular domain;
however, in human brains the presence of an alternatively
spliced TREM2 transcript (TREM2 alt) encoding for
sTREM2 has been reported [13].
In this study we used autopsy brains to quantitate
TREM2 and TREM2alt transcript levels in two cohorts:
one composed of AD and normal control subjects and
the other of p.R47H carriers and non-carriers (wild
type). We also analyzed TREM2 at the protein level in
p.R47H carriers, and compare its N-glycosylation profile
with wild type brains.
Findings
Quantitative analysis of TREM2 transcripts in control and
AD brains
There are at least three TREM2 transcripts that are
expressed in human brain [13]. Variant 1, the longest
TREM2 transcript consists of 5 exons, while variant 3
(the shortest) is an alternatively spliced isoform that
excludes exon 4 (Fig. 1). Exon 4 contains the sequence
for the TREM2 transmembrane domain; thus, variant 3
that was recently detected in human brains [13], likely
encodes for a soluble form of the receptor (sTREM2).
Previous studies using transfected cells suggest that
proteolytic cleavage of the extracellular domain is the
main mechanism by which sTREM2 is generated [11,
14]. Regardless of the mechanism, the potential rele-
vance of sTREM2 as biomarker to monitor AD progres-
sion is highlighted by its elevation in the CSF of AD
patients [15, 16].
In principle, the elevation of sTREM2 in AD patients
could be the result of an overall increase of TREM2 ex-
pression and/or a specific increase in sTREM2 produc-
tion. To address these possibilities, we quantified levels
of total TREM2 transcripts and the alternatively spliced
variant 3 (TREM2alt) in the temporal cortex of normal
control and AD from post-mortem brains.
Demographics of the control and AD cases (cohort A)
used for the analysis are summarized in Table 1. RNA
was reversed transcribed and qPCR was performed using
two sets of TaqMan primers: one that detects all TREM2
mRNA variants and one specific for TREM2alt. Based
on ΔCt calculations, the level of TREM2alt was between
5 and 7 times lower than of all TREM2 transcripts com-
bined. Relative expression levels were determined for all
comparisons using the ΔΔCt method (2-ΔΔCt) and tested
for differences between groups using the Wilcoxon rank
sum test. We found statistically significant increased
levels of TREM2 transcripts in the temporal cortex of
AD subjects when compared to controls (p = 1.14E-05,
Table 2 and Fig. 2a). TREM2alt was also increased in
AD (p = 7.28E-05, Table 2 and Fig. 2a) and the expres-
sion levels of TREM2 and TREM2alt were correlated
(r2 > 0.72, data not shown). The extent of the increase in
AD brains was similar for both total TREM2 and TRE-
M2alt suggesting that the increase is not likely to be
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transcript-specific. To further assess significant results
identified by the non-parametric Wilcoxon rank sum
test (Table 2), we performed multivariable linear regres-
sion, using ΔCt as the expression variable, adjusting for
known technical and biological covariates, and levels of
the microglial marker AIF1 (aka IBA1). Since we used
ΔCt as the expression variable in this analysis, it should
be noted that a negative beta indicates increased ex-
pression (Table 2). We confirmed the association of
increased TREM2 levels in the temporal cortex of AD
compared to controls (p = 2.30E-02, Table 2) and al-
though the increase for TREM2alt was not significant
(p = 1.41E-01, Table 2), the association was in the same
direction. This result indicates that TREM2 levels are
increased in AD even after taking into account the ex-
pression of the microglial marker IBA1; therefore, it is
unlikely that the observed increase in TREM2 expres-
sion is entirely due to increase number of microglial
cells. Furthermore, we observed a positive correlation
between TREM2 and TREM2alt with IBA1 expression
levels in control and AD samples (Fig. 2c).
TREM2 expression analysis in cerebellum (a brain re-
gion with minimal neuronal loss in AD) was confounded
by the low levels of TREM2 in that brain region; how-
ever, the same trend towards increased expression in AD
compared to controls was observed (data not shown).
Similar analysis was performed with RNA from an in-
dependent cohort (B) of p.R47H TREM2 carriers (CT)
and those homozygous for the major allele (CC) (re-
ferred also in the text and Figures as wild type). All
p.R47H carriers had pathologically-confirmed typical
AD, except for one sample that had posterior cortical at-
rophy (PCA), an AD subtype; wild type (WT) non car-
riers used for the analysis were also AD and one was
PCA. The Wilcoxon-rank-sum test indicated higher
TREM2 and TREM2alt levels in carriers of the p.R47H
Table 1 Demographic of studied cases








ADa 33 72.7 (6.2) 17 (52%) 16 (48%) 6.0 (5.0–7.9)
CONTa 33 70.7 (5.7) 18 (55%) 15 (45%) 7.0 (5.3–8.4)
WT (CC)b 26 79.7 (8.5) 19 (73%) 20 (77%) 6.6 (5.5–8.6)
R47H (CT)b 15 81.5 (8.3) 11 (73%) 9 (69%) 6.3 (5.5–8.4)
acohort A bcohort B
Fig. 1 Localization of TaqMan probes for TREM2 transcripts. The cartoon illustrates 3 TREM2 transcripts with their exons. Variant 3 referred in the
text as TREM2alt is devoid of exon 4. The TaqMan probe to detect all TREM2 transcripts spans from exon 2 to exon 3, and the probe to detect
TREM2alt (alt) spans from exon 3 to exon 5. In the bottom of the Figure there is a representation of TREM2 protein with its different domains.
The position of the p.R47H variant in the transcripts and protein is indicated. SP: signal peptide. TM: transmembrane domain





Dx Transcript Median (IQR) p-value Beta (se) p-value
ADa TREM2 3.19 (2.03–4.06) 1.14E-05 −0.51 (0.22) 2.30E–02
ADa TREM2Alt 2.62 (2.10–3.75) 7.28E-05 −0.33 (0.22) 1.41E-01
AD
(R47H)b
TREM2 1.20 (1.04–1.74) 7.61E-02
AD
(R47H)b
TREM2Alt 0.97 (0.75–1.44) 6.02E-01
acohort A bcohort B




























Fig. 2 (See legend on next page.)
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risk allele; however, differences between the two groups
were not statistically significant (Fig. 2b and Table 2).
Quantitative analysis of TREM2 protein in control and AD
brains
Protein analysis was performed in the same brain samples
in which TREM2 transcripts were previously evaluated.
We performed quantitative Western blot to establish if
the increase in TREM2 mRNA in AD samples is reflected
at the protein level. RIPA buffer extracts from temporal
cortexes from a subset of control and AD samples (N = 48
out of 66) analyzed for TREM2 transcripts were used and
the blots were probed with a monoclonal antibody against
the carboxy terminus of TREM2. This antibody allowed
the detection of three TREM2 species: mature (~50 kDa),
immature (~30 kDa), and carboxy terminal fragment
(CTF) (Fig. 3a). The CTF species were identified on West-
ern blots based on its molecular weight and immunoreac-
tivity with a C-terminal antibody (Fig. 3a), but not with a
N-terminal antibody (data not shown). The designation as
mature or immature TREM2 species was based on their
resistance or susceptibility to EnodH and PNGaseF, re-
spectively (Fig. 4c). Quantitation of all TREM2 species
normalized to Iba1 reveals a statistically significant eleva-
tion in AD samples as compared to controls (Fig. 3b). To
evaluate TREM2 processing we also compared the ratio
between immature and mature species and the levels of
CTF species between the two groups. The ratio between
immature and mature TREM2 was significantly higher
(p < 0.001) in the AD samples, but not significant differ-
ences were detected when the levels of CTF species be-
tween controls and ADs were compared (Fig. 3b).
As might be expected given the observed increase of
both TREM2 RNA and protein in AD subjects when
compared with controls, Spearman rank analysis indi-
cated a positive correlation between TREM2 mRNA
and protein values (rho = 0.36, p = 0.012) when assessed
in the same subjects. Our data are in agreement with a
previous study of postmortem human brains that re-
ported higher TREM2 protein levels in AD than in
controls [17].
Expression and deglycosylation profiles of WT and
p.R47H TREM2
To establish if the p.R47H mutation alters either the ex-
pression and/or glycosylation of TREM2, we subjected
brain samples from WT and p.R47H carriers to quanti-
tative Western blot analysis and enzymatic treatments
with glycosidases. The distribution of TREM2 signal
between mature, immature, and CTF species varied
among samples (Fig. 4a), but statistical analysis shows
no significant difference in total TREM2 expression be-
tween WT and p.R47H carriers (Fig. 4b). Furthermore,
the ratio between immature and mature species is not
altered by the presence of the mutation, suggesting that
it does not affect intracellular trafficking of the receptor
(Fig. 4b). We also looked at the impact of p.R47H on
the extent of TREM2 proteolytic cleavage by quantitat-
ing CTF species relative to total TREM2 species in each
sample and found no difference with WT subjects
(Fig. 4b). This data indicates that the p.R47H mutation
does not affect TREM2 delivery to the cell surface
where CTF species are generated. The intracellular
trafficking of TREM2 can be monitored by assessing
modifications to its N-glycan chains using EndoH and
PNGaseF enzymes. EndoH susceptible TREM2 species
(immature) are still in the endoplasmic reticulum
while resistant (mature) have left that compartment.
All N-glycosylated species are susceptible to PNGaseF
regardless of their intracellular localization. Removal
of N-glycan chains from TREM2 by either EndoH or
PNGaseF results in a lower molecular weight of the
protein, a change that can be detected by Western blot.
Figure 4c shows representative deglycosylation experi-
ments of WT and p.R47H samples using EndoH and
PNGaseF enzymes with different proportions of ~50 kDa
and ~30 kDa TREM2 species. We consistently observed
that in WT and p.R47H samples the ~50 kDa species
(mature) was resistant to EndoH and susceptible to
PNGaseF and that the ~30 kDa species (immature) was
susceptible to both enzymes. The nature of the molecu-
lar weight difference between mature and immature
TREM2 species is unknown; however based on the
enzymatic deglycosylation experiments the molecular
weight difference is not due to glycosylation (Fig. 4c).
Our results contrast with a recent study that found
elevated mRNA but decreased protein expression in
p.R47H carriers [18]. Our data indicate a trend, albeit
not significant, towards both higher mRNA and protein
TREM2 levels as a result of the mutation. Furthermore,
our results do not support previous in vitro studies that
suggested that p.R47H affects TREM2 intracellular
(See figure on previous page.)
Fig. 2 Expression of total and alternative spliced TREM2 mRNA in AD and p.R47H carriers. Relative quantitation was performed using 2-ΔΔCt (fold
change) method. For each sample in the AD or p.R47H group the fold change (FC) value is expressed relative to the median value of TREM2 in
control (a) or WT group (b) that was set at 1. The median FC value in AD samples is 3.19 for TREM2 and 2.62 for TREM2alt; and in p.47H carriers is
for TREM2 1.20 and 0.97 for TREM2alt. ***p < 0.0001. ns: not significant. c. Assessment of relative expression levels (2-ΔΔCt) for TREM2 or TREM2alt
indicates a positive association in all the samples (controls and ADs) for both TREM2 transcripts with the microglial marker AIF1 (IBA1) (R square
values of 0.32 and 0.25 for TREM2 and TREM2alt, respectively; and p < 0.0001 for both transcripts)
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trafficking [14, 19]. Rather, our data are more in line
with a recent study showing higher TREM2 levels in
CSF of p.R47H carriers than in controls [12].
In conclusion, we demonstrated that total TREM2 in-
cluding TREM2alt transcript and TREM2 protein levels
are increased in AD. Our study indicates that proteolytic
cleavage of the receptor is likely the main mechanism
for sTREM2 generation in the brain based on the very
low levels of expression of TREM2alt and the detection
of CTF species in brain extracts. Finally, our data sup-
ports the notion that the p.R47H mutation does not
affect processing (i.e., N-glycosylation and cell surface
proteolytic cleavage) of TREM2.
Material and methods
Brains
In the autopsy-confirmed series, all brains were from
the brain bank at Mayo Clinic in Jacksonville. The diag-
nosis of confirmed AD was made according to accepted
neuropathological criteria. All late-onset AD brains an-
alyzed had a Braak neurofibrillary tangle stage of IV or
greater. Brains employed as controls had a Braak stage
a
b
Fig. 3 TREM2 protein expression in control and AD brains. Temporal cortices were extracted with RIPA buffer and 100 μg of the soluble fraction
(supernatant of 20,000 g centrifugation for 30 min) was used for the analyses. a. Western blot of a representative gel probed with a C-terminal
TREM2 antibody, Iba1, and actin antibodies. Three main TREM2 species are indicated: mature, immature and carboxy terminal fragment (CTF). To
confirm the specificity of the C-terminal TREM2 antibody two positive and one negative controls were included. The positive (+) controls were
lysates of a human brain and THP-1 cells (a human monocyte cell line) previously tested with B-3, a well characterized TREM2 antibody. The
negative (−) control was a lysate of 293 cells that do not express endogenous TREM2. b. The signal intensity of all three species TREM2 species,
Iba1, and actin in each sample was quantitated using ImageQuant software and used for plotting TREM2 (all species) normalized to actin and
Iba1 levels, the ratio between immature and mature species, and CTF species normalized to TREM2 (full length: immature and mature species).
***p < 0.0001, **p < 0.001, and ns: not statistically significant
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c
Fig. 4 TREM2 expression and deglycosylation profiles in WT and p.R47H carriers. RIPA extracts from temporal cortices were used for the analyses.
a. Western blot of a representative gel probed with C-terminal TREM2 antibody, Iba1, and actin antibodies. Three main TREM2 species are indicated:
mature, immature and carboxy terminal fragment (CTF). b. The signal intensity in TREM2 species in WT and p.R47H samples (N = 16 for each group)
was quantitated as previously described, and was plotted after normalization to actin and Iba1. The ratio between immature and mature TREM2
species and between CTF species normalized to TREM2 (full length: immature and mature species) were also plotted. c. Soluble fractions from RIPA
buffer brain extracts were incubated in reaction buffers without enzymes (controls) or with endoH (1000U) or PNGaseF (1000U) overnight at 37 °C. The
whole reaction mixture was analyzed by Western blot probed with a C-terminal TREM2 antibody. Blots containing two representative samples from
WT and p.R47H brains are shown
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of less than III. Most had other brain pathology unrelated
to AD and included cerebrovascular pathology, frontotem-
poral dementia, Lewy body diseases, corticobasal degener-
ation, argyrophilic grain disease, multi-system atrophy,
amyotrophic lateral sclerosis, and progressive supranuclear
palsy. No subjects in this study carried familial Alzheimer’s
disease mutations in APP, PSEN or the TREM2 R47H mu-
tation, unless indicated.
qPCR
Total RNA was extracted from 50 mg of frozen tem-
poral cortex and cerebellum of late-onset Alzheimer’s
disease brains and controls with Trizol (Sigma). Pure-
link DNAse (Invitrogen) was used to remove genomic
DNA, and RNA was reverse transcribed to single-
stranded cDNA using the High-Capacity cDNA Archive
Kit from AppliedBiosystems. Quantitative real-time
PCR was performed in triplicate for each sample using
ABI TaqMan Low Density expression Arrays (384-Well
Micro Fluidic Cards) with pre-validated TaqMan Gene
Expression Assays. Glyceraldehyde-3-phosphate dehydro-
genase (GAPDH, Hs02758991_g1) and hypoxanthine
phosphoribosyltransferase 1 (HPRT1, Hs02800695_m1)
were used as housekeeping genes. The following add-
itional TaqMan Gene Expression assays were used:
Hs00219132_m1 to capture all TREM2 transcripts, a
custom assay was designed for TREM2alt (assay
ID:AI89K96), and Hs00610419_g1 for AIF1 (aka IBA1).
Real-time PCR cycle threshold (CT) raw data was col-
lected and exported using the ABI PRISMH SDS soft-
ware version 2.2. The variable ΔCT denotes the difference
between the averaged CT values for the TREM2 tran-
scripts and that for the housekeeping genes. The fold
change (2-ΔΔCt) for each sample was calculated relative to
the median ΔCT in control samples (AD vs control) or
subjects homozygous for the major allele (R47H), as
relevant.
EndoH and PNGaseF treatments
100 μg of RIPA-soluble fractions were boiled for 5 min
in denaturing buffer. After cooling, the samples were in-
cubated with 2 μl of either EndoH (1000U) or PNGaseF
(1000U) overnight at 37 °C in their respective assay
buffers supplemented with 1% NP-40. Both enzymes and
buffers were from New England Biolabs. The whole re-
action was loaded on a gel for Western blot analysis.
Western blot
Temporal cortexes were extracted with RIPA buffer
(Sigma) and soluble fractions were generated by centri-
fugation for 30 min at 20,000 g. Protein concentration
in the RIPA-soluble fractions was determined by BCA
assay and 100 μg from each sample were run on 4–20%
gradient Tris-glycine Novex gels (Invitrogen). Transfer
of the proteins to nitrocellulose membranes was carried
out at 70 V for 2 h. The membranes were then blocked
for 1 h with 5% milk in TBS 0.05% Tween-20 and incu-
bated overnight with the following TREM2 antibodies: a
C-terminal Ab D8I4C (1–500, Cell Signaling) and N-
terminal Ab 175262 (1–500, Abcam). The other primaries
antibodies used were actin (I-19 1–100, Santa Cruz) and
Iba1 (1–2000, Abcam 178847). The blots were washed five
times with TBS 0.05% Twenn-20 and incubated with an
anti-rabbit HRP antibody (1–2000) for 1 h at room
temperature. The blots were developed with SuperSignal
West Femto reagent (Pierce), imaged with the Fujifilm
Luminescent Image Analyzer LAS4000 System, and the
bands were quantitated using ImageQuant software.
Statistical analysis
Relative expression levels were calculated using the
2-ΔΔCt method, and tested for differences between groups
using the Wilcoxon rank sum test with Prism software.
When this test was significant, we used multi-variable lin-
ear regression to further assess the association, using ΔCt
as the expression variable and adjusting for the following
covariates: age at death (years), sex, RNA integrity number
(RIN), qPCR plate and measured levels (ΔCt) of IBA1.
Statistical analyses were performed using the R Statistical
Software (R Foundation for Statistical Computing, version
3.2.3). Prism software was used for statistical analysis of
data presented in Figs. 3 and 4.
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